Search
asciminib (Scemblix)
Indcations:
- treatment of chronic myeloid leukemia
- Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibito
Adverse effects:
- upper respiratory tract infections
- musculoskeletal pain
- thrombocytopenia
- neutropenia
- anemia
- hypertriglyceridemia
- increase in serum creatine kinase & serum alanine aminotransferase
Mechanism of action:
- acts as a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor.
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- Chustecka Z
FDA Approves Asciminib, Drug With Novel Action in CML.
Medscape. November 02, 2021
https://www.medscape.com/viewarticle/962073